ZyVersa is a clinical-stage specialty biopharmaceutical company leveraging advanced proprietary technologies to develop first-in-class drugs for patients with inflammatory or kidney diseases with high unmet medical needs.<br /><br />The company currently has two novel drugs in the development pipeline. IC 100, an “ASC inflammasome inhibitor” treats inflammatory diseases. VAR200 is a “Cholesterol Efflux Mediator” targeting kidney disease.
